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Background: There may be difficulties in the use of self report measurements in patients with cognitive
impairment or serious mood disturbances which interfere with reliable self assessment, as may be the case
in multiple sclerosis (MS). In such cases proxies may provide valuable information. However, before using
any questionnaires in a proxy sample, the questionnaire should be evaluated for proxy use.
Objective: To evaluate the psychometric properties of the 29 item Multiple Sclerosis Impact Scale (MSIS-
29) when used by proxies of MS patients.
Methods: A sample of 62 partners of MS patients completed the MSIS-29. The data were evaluated for the
psychometric criteria of the MSIS-29, including data quality, scaling assumptions, acceptability, reliability,
validity, and responsiveness.
Results: Psychometric evaluation was satisfactory; data quality was high, and scaling assumptions and
acceptability were good. Reliability was high (a.0.80). Findings were consistent with results of a
psychometric evaluation in a patient sample.
Conclusions: The MSIS-29 can be used reliably in proxies of patients with MS. As a next step the relation
between data obtained from patients and proxies needs to be studied, focusing on factors that may affect
agreement and discrepancies.
I
n recent years, there has been increasing use of self report
measurements for assessing quality of life, disease impact,
or disability. The underlying assumption when using self
report measurements is that the patient fully understands the
questions and can give a reliable judgment on their situation.
Problems may arise when the cognitive or communication
abilities are insufficient. Moreover, emotional factors may
interfere with self assessment, which will affect reliability.
Therefore self report measurements may be less suitable in
cases of cognitive dysfunction or severe mood disturbance.
When applying self report measurements, the presence of
such factors could lead to unreliable information or loss of
information. It has been suggested that in these situations
the use of proxies (for example, partners, relatives, or close
friends) to assess the situation of the patient should be
considered.1 These considerations are relevant for multiple
sclerosis (MS) because self report measures are often used in
MS, and both cognitive decline and severe mood disturbances
may be present during the course of the disease.2 3 These
disorders could lead to invalid self reporting of quality of
life,4–8 although there are also papers suggesting that in
cognitively impaired and depressed patients self reports may
be valid.9–12 Nevertheless, proxy measurements could be
important in MS and useful under certain circumstances. We
are not aware of any studies that have assessed systematically
the value and limitations of proxy measurements in MS. Of all
available self report measurements that can be used in MS, the
Multiple Sclerosis Impact Scale (MSIS-29) is disease specific
and has been rigorously evaluated for its psychometric proper-
ties.13 We therefore evaluated the use of the MSIS-29, which
measures physical and psychological disease impact, in proxies.
However, the MSIS-29 was not developed for use in proxies of
MS patients. Thus it is essential that the questionnaire is
validated first by using standard psychometric tests before using
the scale to evaluate differences and agreement between
patients and proxies.1
The focus of the present study was to evaluate the
psychometric properties of the MSIS-29 when used by
proxies of patients with MS.
METHODS
Study sample
For this study, partners of MS patients were asked to
complete the MSIS-29 as proxies. Partners were recruited in
two ways. The first was through an ongoing study of MS
patients at the outpatient clinic which required the presence
of a healthy control. Those controls who were partners of the
patients were asked to participate in the present study by
completing the MSIS-29 during the initial visit and at the
time of a six month follow up visit. Secondly, a group of
partners of patients who visited the outpatient clinic was
asked to complete the MSIS-29 twice, with a two week
interval, to measure test-retest reliability. The Expanded
Disability Status Scale (EDSS), the Guy’s Neurological
Disability Scale (GNDS), and the MS subtype were available
for all patients.
The medical ethics committee of the VU University Medical
Centre approved the study protocol. Informed consent was
obtained from all participants.
Measures and procedures
The MSIS-29 is a 29 item measurement, which assesses the
physical and psychological impact of MS on affected
individuals; it is a self report questionnaire consisting of 20
and 9 items, respectively. Scores on the individual items are
added and then transformed to a 0–100 scale, thereby
generating two summary scores (for physical and psycholo-
gical impact). Higher scores indicate worse health.13 For this
study the Dutch version of the MSIS-29 was used, which is
an in-house translation of the original English version that
was subsequently validated in a large study across eight
European countries.14 The partners were asked to complete
the MSIS-29 after being instructed to keep the following
question in mind: ‘‘How do you think the patient experiences
the impact of MS on his/her life?’’ Standard psychometric
Abbreviations: EDSS, Expanded Disability Status Scale; ES, effect size;
GNDS, Guy’s Neurological Disability Scale; ICC, intraclass correlation
coefficient; MS, multiple sclerosis; MSIS, Multiple Sclerosis Impact Scale
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methods were used to evaluate the following psychometric
properties: data quality, scaling assumptions, acceptability,
reliability, responsiveness, and validity. Evaluation was done
according to the methods used in the health technology
assessment report of Hobart et al.13 Table 1 gives a summary
of the psychometric criteria that were applied.13
Reliability
The MSIS-29 and instructions were given to the patient for
the proxy to complete at home. After a two week interval the
proxy received the MSIS-29 for the second time by postal
survey. Test–retest reliability was calculated by intraclass
correlation coefficient (ICC).
Table 1 Psychometric criteria
Psychometric property Criteria
Data quality Missing items ,10%
High percentage of computable scale scores
High item test–retest reliability: r >0.50
Scaling assumptions Similar response option frequency distribution
Skewness between 21 and +1
Similar means and standard deviations
Similar and substantial item-total correlations: r .0.30
Acceptability Scores should span the full scale range
Mean scores should be around the midpoint
Floor and ceiling effect ,20%
Skewness between 21 and +1
Reliability Cronbach’s a .0.80
Scale test–retest reliability (ICC) .0.80
Responsiveness Correlation between change score and transition score should be high
Clinically important difference: 0.5 = small, 1.0 = moderate, 1.5 large
Validity
Internal validity Moderate intercorrelation: r=0.30–0.70
External validity High correlation between MSIS-29 physical scale and EDSS
Low correlation between MSIS-29 psychological scale and EDSS
High correlation between MSIS-29 physical scale and GNDS
Low correlation between MSIS-29 psychological scale and GNDS
Group differences validity Similar and low correlations between men and women
Similar and low correlations for age
Hypotheses Mean physical MSIS-29 score for different groups of the EDSS score:
MSIS-29 score (EDSS 0.0–3.5) , MSIS-29 score (EDSS 4.0–6.0)
MSIS-29 score (EDSS 0.0–3.5) , MSIS-29 score (EDSS >6.5)
MSIS-29 score (EDSS 4.0–6.0) , MSIS-29 score (EDSS >6.5)
Mean physical MSIS-29 score for different groups of the GNDS score:
MSIS-29 score (GNDS ,15) , MSIS-29 score (GNDS >15)
Mean physical and psychological MSIS-29 scores for different MS subtypes:
MSIS-29 score (RR) , MSIS-29 score (SP)
MSIS-29 score (RR) , MSIS-29 score (PP)
MSIS-29 score (SP) , MSIS-29 score (PP)
EDSS, Expanded Disability Status Scale; GNDS, Guy’s Neurological Disability Scale; MS, multiple sclerosis; MSIS-
29, Multiple Sclerosis Impact Scale; PP, primary progressive; RR, relapsing–remitting; SP, secondary progressive.
Table 2 Characteristics of proxies and patients
Patients Proxies
Female (n) 42 20
Age (years) (mean (SD)) 48 (8.9) 49 (9.0)
Time since MS onset (years) (mean (SD)) 13 (7.2) –
Type of MS (n)
Relapsing–remitting 28 –
Secondary progressive 21 –
Primary progressive 11 –
Other 2 –
EDSS
0.0–3.5 17 –
4.0–6.5 32 –
>6.5 10 –
Missing 3
GNDS
,15 26 –
>15 32 –
Missing 4
EDSS, Expanded Disability Status Scale; GNDS, Guy’s Neurological Disability Scale; MS, multiple sclerosis.
1678 van der Linden, Kragt, Klein, et al
www.jnnp.com
Responsiveness
A method to detect clinically important change over time is
by comparing change scores (baseline score minus follow up
score) with an external criterion of change, such as a
transition question. This is also referred to as the retro-
spective method.13 15 16 In this study we compared the change
scores of the MSIS-29 for the two domains, using the
following transition question: ‘‘When you compare the health
status of the patient at this moment with that of six months
ago (baseline study), would you say that it is: better, the
same, or worse?’’ Although patients did not have an
intervention, change could have been induced by the passage
of time.15 Responsiveness can then be determined in different
ways. One method is to calculate the correlation between the
change scores and the transition score; a high correlation
indicates a greater responsiveness.13 Another method is by
calculating the minimum clinically important difference. This
is done by dividing the mean change score for improved/
deteriorated patients by the mean change score of unchanged
patients. A change of 0.5 is considered small, 1.0 moderate,
and 1.5 large.13 15 Finally, effect sizes (ES) were calculated by
dividing the mean change score by the standard deviation of
the admission score. Effect sizes are interpreted as small at
ES ,0.20, medium at ES = 0.50, and moderate at ES
.0.80.13
Validity
Internal validity was determined by calculating the inter-
correlations between the physical and the psychological
domain. External validity was examined by correlations
between the two MSIS-29 domains and the EDSS and
GNDS. Group differences validity was assessed by comparing
both scales with variables such as age and sex.
Validity was also determined by comparing the mean
MSIS-29 proxy score between MS subtypes and weighing
against patient scores on the GNDS and the EDSS. The mean
scores on the GNDS, EDSS, and the MS subtype were divided
into different groups and it was hypothesised that the
corresponding mean MSIS-29 proxy scores for these different
groups should differ significantly. The GNDS score was
divided into two groups based on the median:(15 and .15.
The EDSS score was divided into three groups: EDSS 0.0–3.5,
EDSS 4.0–6.0, and EDSS >6.5. MS subtype was also divided
into three groups: relapsing remitting (RR), secondary
progressive (SP), and primary progressive (PP).
Independent t tests were done to compare the different
groups. The mean MSIS-29 proxy scores for GNDS and EDSS
were compared only for the physical domain as the GNDS
and the EDSS do not have a psychological domain. The MS
subtype was compared for both domains, given that the
subtype might influence the psychological impact of MS.
Table 1 shows the hypotheses, which were defined prospec-
tively. Correlations were calculated for age and sex.
RESULTS
In all, 62 partners were recruited as proxy for the study.
Table 2 shows the characteristics of the partners and the
patients.
Data quality
These results are shown in table 3. The percentage of missing
data was low for both scales, and the computable scale scores
were high. Scales could be calculated for at least 93.5%. Item
test–retest was 0.87 for the physical domain and 0.83 for the
psychological domain.
Scaling assumptions
Scaling assumptions are shown in table 3. Similar item
means and standard deviations were found for both scales.
Frequency distributions showed to be symmetrical for both
scales. Skewness for the physical scale was between 21 and
1, but skewness for the psychological scale was slightly out of
range (+1.235). Item-total correlations for both scales were
high: the physical scale ranged from 0.55 to 0.85 and the
psychological scale from 0.41 to 0.86, both therefore fulfilling
the correlation criterion (.0.30). There was a definite scaling
Table 3 Psychometric properties for the physical and psychological MSIS-29 impact
scales
Psychometric property MSIS-29 physical MSIS-29 psychological
Data quality
Item missing data 0.5% 0.1%
Computable scale scores 93.5% 98.4%
Item test–retest reliability (ICC) 0.87 0.83
Scaling assumptions
Item mean scores range 2.1 to 3.3 1.8 to 2.9
Item SD range 1.0 to 1.5 1.1 to 1.4
Item skewness range 20.499 to +0.742 0.201 to +1.235
Item-total correlation range 0.55 to 0.85 0.41 to 0.86
Acceptability
Observed scale score range 0 to 91.3 0 to 91.7
Scale score (mean (SD)) 43.9 (24.2) 32.7 (23.2)
Floor/ceiling effect (%) 4.7/1.6 1.6/1.6
Skewness 20.231 0.459
Reliability
Cronbach’s a 0.96 0.90
Scale test–retest reliability (ICC) 0.87 0.83
Responsiveness
Correlation 0.07 0.24
Effect size 0.05 0.02
Clinically important difference:
improved patients (n = 30) 0.6 0.8
deteriorated patients (n = 7) 0.2 1.1
ICC, intraclass correlation coefficient; MSIS-29, Multiple Sclerosis Impact Scale.
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success of 50% and 44% for the physical and psychological
scale, respectively. Consequently the criterion of 65% or larger
was not satisfied.
Acceptability
The score ranged from 0–91.3 for the physical scale and 0–
91.7 for the psychological scale (table 3). The physical scale
was slightly skewed (22.31). Floor and ceiling effects were
small and did not exceed the predefined maximum of 20%.
Scale midpoints were near the middle and standard devia-
tions were almost equal.
Reliabili ty
The internal consistency was high (table 3): 0.96 for the
physical scale and 0.90 for the psychological scale. In all, 30
proxies completed both questionnaires for the test–retest
study, which resulted in a test–retest reproducibility of 0.87
for the physical scale and 0.83 for the psychological scale.
Responsiveness
The correlations between the change score and the transition
score were 0.07 for the physical scale and 0.24 for the
psychological scale (table 3). The minimum clinically
important change was small to moderate. The effect sizes
were minimal for both domains.
Validity
Validity assessments are shown in tables 4 and 5. Internal
validity was moderate, with an intercorrelation of 0.65
(table 4). The EDSS score showed a higher correlation of
0.66 with the physical domain than with the psychological
domain. Correlation for GNDS with the physical domain was
slightly higher (0.69) than for the EDSS score. Both MSIS-29
scales showed moderate correlations with age and sex.
Table 5 shows the hypothesised group differences with
accompanying p values. Independent t tests were significant
except for the difference between the mean MSIS-29 physical
score (SP) and mean MSIS-29 physical score (PP). This was
also true for the group differences of the mean MSIS-29
psychological scores per MS subtype.
DISCUSSION
Our aim in this study was to evaluate the psychometric
properties of the MSIS-29 when used by proxies. Standard
techniques were applied to evaluate data quality, scaling
assumptions, acceptability, reliability, responsiveness, and
validity. This was done according to psychometric criteria
that were also used for the psychometric evaluation of the
MSIS-29 in a patient sample.13 Psychometric properties were
satisfactory for most of the criteria. Data quality was high.
Scaling assumptions and acceptability were good, although
the score did not span the full range for both domains and
the physical scale was slightly skewed. High values for
reliability were found. Responsiveness showed minimal effect
sizes and poor correlations. This might have reflected the fact
that change was caused by natural progression over time
rather than by a treatment effect following an intervention.
Natural progression may be harder to detect by proxies than
the effect of a treatment. Taking into account the relatively
small sample size we think that the responsiveness results
should be interpreted with caution.
The validity of the MSIS-29 was established in different
ways. Correlation between the EDSS and the physical scale
was high, which could be expected as the EDSS measures
disability. Correlations between the two scales and the GNDS
were both moderate, which is probably explained by the fact
that the GNDS contains questions on both physical and
psychological topics. Correlations for both MSIS-29 scales
and the variables age and sex were low, indicating that
neither scale was biased by these variables. Significant
differences in mean MSIS-29 scores were found for the
different groups defined on the basis of GNDS, EDSS, and
MS subtype. Of the 10 prior hypotheses, six were significantly
confirmed, especially those referring to the physical domain.
Partners of patients with an EDSS score >6.5 scored
significantly higher on the MSIS-29 physical score than
partners of patients with a low EDSS score of 0.0 to 3.5.
Table 4 Pearson correlation for age, sex,
EDSS, and GNDS scores with the physical and
psychological MSIS-29 impact scales
Variable
MSIS-29
physical
MSIS-29
psychological
Age 0.07 0.29
Sex 0.09 0.13
EDSS 0.66 0.25
GNDS 0.69 0.56
MSIS-29
psychological
0.65 1.0
EDSS, Expanded Disability Status Scale; GNDS, Guy’s
Neurological Disability Scale; MSIS-29, Multiple Sclerosis
Impact Scale.
Table 5 Validity
Hypothesised group differences for corresponding MSIS-29
scores in groups of EDSS, GNDS, and MS subtype
p
Value
EDSS
MSIS-29 score (EDSS 0.0–3.5) , MSIS-29 score (EDSS 4.0–6.0) 0.001
MSIS-29 score (EDSS 0.0–3.5) , MSIS-29 score (EDSS >6.5) 0.000
MSIS-29 score (EDSS 4.0–6.0) , MSIS-29 score (EDSS >6.5) 0.000
GNDS
MSIS-29 score (GNDS ,15) , MSIS-29 score (GNDS >15) 0.000
MS subtype (physical)
MSIS-29 score (RR) , MSIS-29 score (SP) 0.001
MSIS-29 score (RR) , MSIS-29 score (PP) 0.001
MSIS-29 score (SP) , MSIS-29 score (PP) 0.584
MS subtype (psychological)
MSIS-29 score (RR) , MSIS-29 score (SP)` 0.052
MSIS-29 score (RR) , MSIS-29 score (PP) 0.195
MSIS-29 score (SP) , MSIS-29 score (PP) 0.706
EDSS, Expanded Disability Status Scale; GNDS, Guy’s Neurological Disability Scale; MS, multiple sclerosis; MSIS-
29, Multiple Sclerosis Impact Scale; PP, primary progressive; RR, relapsing–remitting; SP, secondary progressive.
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Proxies believed that patients with a high EDSS score
experience a greater physical impact of MS than patients
with a lower EDSS score. The same can be said about patients
with a high GNDS score: partners of patients with a GNDS
score .15 scored significantly higher on the MSIS-29
physical score than partners of patients with a GNDS score
(15. This shows that differences in the EDSS score and the
GNDS score are reflected in the MSIS-29 score of proxies, and
that the MSIS-29 measures what it is supposed to measure
when completed by proxies. The MSIS-29 physical score only
differed between the subtypes RR and SP and between RR
and PP, indicating that proxies do not make a distinction
between the subtypes SP and PP. No significant differences
were found between the MS subtypes on the psychological
domain. Whether this is in line with the opinion of the
patient remains to be investigated. A limitation of the present
study in this respect is the lack of other quality of life
measurements with psychological domains such as the 36
item short form health survey (SF-36) and the general health
questionnaire (GHQ), which precludes direct comparisons.
Other research showed that proxies are better at detecting the
more observable domains, such as physical problems, than
the subjective domains, such as psychological problems.17
Overall, the results showed resemblance with the psycho-
metric properties when used by patients.13 18 19 In summary,
our results indicate that the MSIS-29 also is a reliable and
valid instrument when used by proxies. This creates a solid
basis for further use of MSIS-29 proxy measurements in MS.
As a next step the relation between data on proxy versus self
reports needs to be studied, focusing on factors that may
affect agreement and discrepancies.
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